Primary chemoradiation with cisplatin versus cetuximab for locally advanced head and neck cancer: a retrospective cohort study.
Cetuximab
Chemoradiation therapy
Cisplatin
HPV/p16
Head and neck squamous cell carcinoma
Journal
Experimental hematology & oncology
ISSN: 2162-3619
Titre abrégé: Exp Hematol Oncol
Pays: England
ID NLM: 101590676
Informations de publication
Date de publication:
2020
2020
Historique:
received:
13
05
2020
accepted:
29
07
2020
entrez:
11
8
2020
pubmed:
11
8
2020
medline:
11
8
2020
Statut:
epublish
Résumé
To explore the efficacy of primary chemoradiation with cisplatin versus cetuximab with respect to HPV/p16 and smoking statuses. We retrospectively reviewed patients from our center with locally advanced non-nasopharyngeal head and neck squamous cell carcinoma (HNSCC) who received primary chemoradiation with cisplatin or cetuximab between 2006 and 2018. The median OS for cisplatin (n = 66) was not reached versus 132 months when treated with cetuximab (n = 55) (p = 0.03). For HPV/p16-positive patients, we found the median OS for cisplatin (n = 34) was not reached versus 60 months with cetuximab (n = 21) (p = 0.036). In the smoking group, the median OS was not reached in the cisplatin group (n = 44) versus 60 months when treated with cetuximab (n = 32) (p = 0.03). HPV/p16-positive and smoking cohorts treated with cisplatin-based chemoradiotherapy had a significantly better OS versus cetuximab.
Identifiants
pubmed: 32775042
doi: 10.1186/s40164-020-00175-1
pii: 175
pmc: PMC7409407
doi:
Types de publication
Journal Article
Langues
eng
Pagination
19Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
Int J Radiat Oncol Biol Phys. 1996 Dec 1;36(5):999-1004
pubmed: 8985019
Genome Biol. 2011;12(4):R41
pubmed: 21527027
Head Neck. 2015 Mar;37(3):386-92
pubmed: 24431011
Arch Pathol Lab Med. 2018 May;142(5):559-597
pubmed: 29251996
Lancet. 2019 Jan 5;393(10166):40-50
pubmed: 30449625
Oral Maxillofac Surg Clin North Am. 2014 May;26(2):123-41
pubmed: 24794262
Lancet Oncol. 2010 Aug;11(8):781-9
pubmed: 20451455
BMC Bioinformatics. 2011 Aug 04;12:323
pubmed: 21816040
Radiother Oncol. 2013 Sep;108(3):489-94
pubmed: 24060179
Oncotarget. 2016 Nov 8;7(45):74362-74379
pubmed: 27556186
Am J Clin Oncol. 2016 Feb;39(1):27-31
pubmed: 24401670
Lancet. 2019 Jan 5;393(10166):5-7
pubmed: 30449624
Nature. 2015 Jan 29;517(7536):576-82
pubmed: 25631445
Cancer Res. 1989 Jul 15;49(14):4024-9
pubmed: 2736543
N Engl J Med. 1993 Jan 21;328(3):184-94
pubmed: 8417385
Sci Rep. 2019 Sep 19;9(1):13564
pubmed: 31537844
Cancer. 2019 Feb 1;125(3):406-415
pubmed: 30341983
Nat Genet. 2013 Oct;45(10):1134-40
pubmed: 24071852
J Clin Oncol. 2016 Apr 20;34(12):1300-8
pubmed: 26712222
Lancet. 2019 Jan 5;393(10166):51-60
pubmed: 30449623
Front Oncol. 2016 Aug 31;6:199
pubmed: 27630826